IIR's 13th Annual EDC and Beyond
13th Annual EDC & Beyond
April 28-30, 2009
Rosen Shingle Creek, Orlando, FL
www.iirusa.com/edc
Contact: Amy Xu at axu@iirusa.comRegister with Priority Code: XP1409ACT
IIR’s 13th annual EDC event puts the “Beyond” into your e-clinical systems, addressing the full e-clinical spectrum of technology and usage for optimal synergistic performance.
Join us as experts from sponsor companies, CROs, investigative sites and e-clinical service providers come together to share strategies that address the full spectrum of the most important EDC issues BEYOND just data capture, including:
- Integrating multiple platforms
- Engaging sites
- Reducing redundancies
- Implementing new standards
- Incorporating safety reporting
Led by a notable speaking faculty, including Keynote Presenter NFL legend Terry Bradshaw, take part in comprehensive workshops, interactive sessions, and new case studies and panel discussions so you can bring back the latest ways of integrating e-technologies into coherent systems, using e-clinical beyond just data capture, implementing industry standardization initiatives, and engaging clinical site preferences. Visit our website at www.iirusa.com/edc for full agenda details.
Plus, take your networking beyond just EDC. This conference is co-located with the 18th annual Partnerships with CROs event! Maximize your conference experience by networking with over 600 companies and 1800 clinical professionals!
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
